Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.

about

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer Precision oncology: neither a silver bullet nor a dream.

P2860

Q28079253-533AFFAA-1137-4A4E-BA9E-BE4F10F8AE17 Q47737073-86CFCFED-4A93-421C-ACA2-29B8C3BEEC7A

P2860

Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q51139197

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Profile of the therascreen® EG ...... in non-small cell lung cancer.

@en

Profile of the therascreen® EG ...... in non-small cell lung cancer.

@nl

type

Item

label

Profile of the therascreen® EG ...... in non-small cell lung cancer.

@en

Profile of the therascreen® EG ...... in non-small cell lung cancer.

@nl

prefLabel

Profile of the therascreen® EG ...... in non-small cell lung cancer.

@en

Profile of the therascreen® EG ...... in non-small cell lung cancer.

@nl

P1476

Profile of the therascreen® EG ...... in non-small cell lung cancer.

@en

P2093

Chia-Chi Lin

http://www.w3.org/2001/XMLSchema#string

Emily Han-Chung Hsiue

http://www.w3.org/2001/XMLSchema#string

James Chih-Hsin Yang

http://www.w3.org/2001/XMLSchema#string

Jih-Hsiang Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

Liquid biopsies: genotyping circulating tumor DNA

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

A sequencing method based on real-time pyrophosphate

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

P304

1251-1257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737159.2016.1248414

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27737606

http://www.w3.org/2001/XMLSchema#string

Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.

about

P2860

P2860

Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698